Geron Corp
$1.30
-$0.02 (-1.52%)
$1.29Day Range$1.33
Key Statistics
Market Cap
$848.06M
Shares Outstanding
642.5M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jul 31, 1996
Round Lot
100
Locale
US
Trading Data
Day Open
$1.32
Day High
$1.33
Day Low
$1.29
Volume
17.24M
VWAP
$1.30
Prev Close
$1.32
Transactions
--
Acc. Volume
--
About Geron Corp
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
PHARMACEUTICAL PREPARATIONSSIC 2834258 employees919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA, 94404(650) 473-7700IPO Jul 31, 1996US / STOCKSActiveWebsite
Identifiers
- CIK
- 0000886744
- Composite FIGI
- BBG000GX1891
- Share Class FIGI
- BBG001S6TSX4
- Ticker Root
- GERN
- SIC Code
- 2834
About Geron Corp (GERN) Stock
Geron Corp (GERN) closed the 2026-09-18 session at $1.30, down 1.52% versus the previous close (-0.02). The stock opened at $1.32 and traded between $1.29 and $1.33 during that session. Session trading volume was 17.2M shares. The volume-weighted average price (VWAP) is $1.30.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Geron Corp has a market capitalization of $848.1 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. GERN is listed on the XNAS exchange. The company employs approximately 258 people. Geron Corp is headquartered in FOSTER CITY, CA. The recorded listing date is 1996-07-31.
On this page you can find market GERN stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.